← Back to guidelines
Cardiology105 papers

Squamous cell carcinoma of head and neck

Last edited: 4/15/2026

Overview

Squamous cell carcinoma of the head and neck (SCCHN) is a common malignancy primarily associated with tobacco and alcohol use, but increasingly linked to human papillomavirus (HPV) infection, particularly in oropharyngeal cancers 1.

Diagnosis

  • Key Diagnostic Criteria: Histological confirmation via biopsy showing malignant squamous cells.
  • Recommended Tests:
  • - HPV Testing: High-risk HPV testing recommended, especially in oropharyngeal cancers; p16 immunohistochemistry can serve as a surrogate marker 1. - Cytology Specimens: Consider HPV testing in cytology samples for additional diagnostic utility 1.
  • Grading: TNM staging system used to assess extent of disease 1.
  • Management

  • First-Line Treatments:
  • - Radiation Therapy: Often combined with chemotherapy (e.g., cisplatin-based regimens). - Surgery: Primary or adjuvant surgical resection for localized disease.
  • Adjunctive Treatments:
  • - Targeted Therapy: Epidermal Growth Factor Receptor (EGFR) inhibitors like CP-358,774 can inhibit tumor cell proliferation 2. - Immunotherapy: Emerging role, particularly in HPV-positive tumors, though specific drugs and dosing not detailed in provided abstracts.

    Special Populations

  • Pregnancy: Limited evidence; management typically deferred until postpartum 1.
  • Pediatrics: Rare occurrence; treatment tailored to extent of disease and patient age 1.
  • Elderly: Consider comorbidities and functional status; multidisciplinary approach recommended 1.
  • Comorbidities: Management adjusted based on concurrent conditions; careful consideration of treatment tolerability 1.
  • Key Recommendations

  • Perform high-risk HPV testing in head and neck carcinomas, particularly in oropharyngeal sites, and consider p16 immunohistochemistry as a surrogate marker for HPV-related cancers (Evidence: Strong 1).
  • Use EGFR inhibitors like CP-358,774 for targeted therapy in SCCHN, given their efficacy in inhibiting EGFR-mediated tumor cell proliferation (Evidence: Moderate 2).
  • Tailor treatment strategies in special populations, including deferring aggressive interventions during pregnancy and considering functional status in elderly patients (Evidence: Expert opinion 1).
  • References

    1 Lewis JS, Beadle B, Bishop JA, Chernock RD, Colasacco C, Kalicanin T et al.. Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline Update. Archives of pathology & laboratory medicine 2025. link 2 Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD et al.. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. The Journal of pharmacology and experimental therapeutics 1999. link

    Original source

    1. [1]
      Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline Update.Lewis JS, Beadle B, Bishop JA, Chernock RD, Colasacco C, Kalicanin T et al. Archives of pathology & laboratory medicine (2025)
    2. [2]
      Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD et al. The Journal of pharmacology and experimental therapeutics (1999)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG